Skip to main content

Advertisement

SpringerLink
Log in

Prostate cancer

A new standard-of-care for advanced-stage disease

  • News & Views
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

First-line, potent androgen blockade for patients with newly diagnosed, advanced-stage, castration-sensitive prostate cancer is confirmed as an effective strategy by data from the STAMPEDE and LATITUDE trials. Herein, we highlight the benefits, discuss caveats and consider the clinical care implications of these findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

    Article  CAS  Google Scholar 

  2. Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2015).

    Article  CAS  Google Scholar 

  3. James, N. D. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387, 1163–1177 (2016).

    Article  CAS  Google Scholar 

  4. Gravis, G. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 14, 149–158 (2013).

    Article  CAS  Google Scholar 

  5. Sweeney, C. et al. Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naïve metastatic prostate cancer (PrCa): E3805 CHAARTED trial. Ann. Oncol. 27 (Suppl. 6), 720PD (2016).

    Google Scholar 

  6. Karantanos, T. et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur. Urol. 67, 470–479 (2015).

    Article  CAS  Google Scholar 

  7. James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 (2017).

    Article  CAS  Google Scholar 

  8. Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352–360 (2017).

    Article  CAS  Google Scholar 

  9. Xie, W. et al. Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP). Ann. Oncol. 27 (Suppl. 6), 717O (2016).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anis A. Hamid and Christopher J. Sweeney are at the Department of Genitourinary Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.,

    Anis A. Hamid & Christopher J. Sweeney

Authors
  1. Anis A. Hamid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher J. Sweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher J. Sweeney.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hamid, A., Sweeney, C. A new standard-of-care for advanced-stage disease. Nat Rev Clin Oncol 14, 592–593 (2017). https://doi.org/10.1038/nrclinonc.2017.120

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.120

  • Springer Nature Limited

Search

Navigation